Search results
Showing 1021 to 1035 of 2010 results for nice guidelines
Evidence-based recommendations on adalimumab (Humira), etanercept (Enbrel) and ustekinumab (Stelara) for plaque psoriasis in children and young people.
NICE has developed a medtech innovation briefing (MIB) on Optowire for measuring fractional flow reserve .
NICE has developed a medtech innovation briefing (MIB) on PIUR tUS for abdominal aortic aneurysm surveillance and endovascular aneurysm repair endoleak detection .
NICE has developed a medtech innovation briefing (MIB) on the Quantitative Timed Up and Go (QTUG)
NICE has developed a medtech innovation briefing (MIB) on Thora 3Di for assessing asthma in children .
Evidence-based recommendations on futibatinib (Lytgobi) for previously treated advanced cholangiocarcinoma with FGFR2 fusion or rearrangement in adults.
Show all sections
Evidence-based recommendations on Memokath 051 Ureter stent for ureteric obstruction.
NICE's guidance executive is made up of executive directors, guidance centre directors and senior team members.
NICE wants as many people as possible to be able to use our services, and we have designed it to be accessible.
Mepilex Border Heel and Sacrum dressings for preventing pressure ulcers (HTG495)
Evidence-based recommendations on Mepilex Border Heel and Sacrum dressings for preventing pressure ulcers.
Kendall DL for ECG monitoring in people having cardiac surgery (MIB177)
NICE has developed a medtech innovation briefing (MIB) on Kendall DL for ECG monitoring in people having cardiac surgery .
Evidence-based recommendations on darolutamide (Nubeqa) with androgen deprivation therapy and docetaxel for hormone-sensitive metastatic prostate cancer in adults.
Fluorouracil chemotherapy: The My5‑FU assay for guiding dose adjustment (HTG360)
Evidence-based recommendations on the My5-FU assay for measuring levels of 5-flurouracil (5-FU) in patients having chemotherapy, to help guide changes to the dose of 5-FU.
Awaiting development Reference number: GID-TA11907 Expected publication date: TBC
NICE has developed a medtech innovation briefing (MIB) on microINR for anticoagulation therapy .